Meitav Investment House Ltd. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 44.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 4,409 shares of the biopharmaceutical company’s stock after buying an additional 1,348 shares during the period. Meitav Investment House Ltd.’s holdings in Gilead Sciences were worth $336,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Altshuler Shaham Ltd boosted its stake in Gilead Sciences by 7.0% in the 4th quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 121 shares during the period. Intercontinental Wealth Advisors LLC increased its stake in Gilead Sciences by 2.4% in the 2nd quarter. Intercontinental Wealth Advisors LLC now owns 5,458 shares of the biopharmaceutical company’s stock worth $421,000 after acquiring an additional 126 shares during the last quarter. Baker Tilly Wealth Management LLC increased its stake in Gilead Sciences by 2.3% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 5,694 shares of the biopharmaceutical company’s stock worth $439,000 after acquiring an additional 128 shares during the last quarter. Pinkerton Retirement Specialists LLC grew its stake in shares of Gilead Sciences by 2.8% in the 1st quarter. Pinkerton Retirement Specialists LLC now owns 4,703 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 129 shares in the last quarter. Finally, DGS Capital Management LLC grew its stake in shares of Gilead Sciences by 2.0% in the 1st quarter. DGS Capital Management LLC now owns 6,570 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 131 shares in the last quarter. Hedge funds and other institutional investors own 82.33% of the company’s stock.
Insider Activity at Gilead Sciences
In related news, insider Merdad Parsey sold 1,501 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total transaction of $115,561.99. Following the sale, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total transaction of $115,561.99. Following the completion of the sale, the insider now owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the sale, the chief financial officer now directly owns 104,003 shares of the company’s stock, valued at approximately $8,320,240. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Gilead Sciences Price Performance
Shares of GILD opened at $75.45 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.20 and a current ratio of 1.34. The company has a 50 day moving average price of $76.82 and a 200-day moving average price of $77.30. Gilead Sciences, Inc. has a fifty-two week low of $72.87 and a fifty-two week high of $89.74. The stock has a market capitalization of $94.01 billion, a PE ratio of 16.19, a PEG ratio of 1.00 and a beta of 0.32.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.38. The company had revenue of $7.05 billion for the quarter, compared to analyst estimates of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. Gilead Sciences’s revenue was up .1% compared to the same quarter last year. During the same period last year, the company posted $1.90 earnings per share. Equities analysts predict that Gilead Sciences, Inc. will post 6.76 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 64.38%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
- Five stocks we like better than Gilead Sciences
- Upcoming IPO Stock Lockup Period, Explained
- MarketBeat Week in Review – 11/13 – 11/17
- How to Invest in Cannabis, Step by Step
- 3 large caps with red hot RSIs with upside
- What Is Dividend Yield and How Do You Calculate It?
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.